Intravenous glucose suppresses glucose production but not proteolysis in extremely premature newborns

David E. Hertz, Cheryl A. Karn, Ya Mei Liu, Edward A. Liechty, Scott Denne

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

To ascertain whether the inability to suppress glucose production and increase glucose utilization in response to glucose infusion is an inherent characteristic of immature individuals, we determined glucose rate of appearance (Ra) in minimally stressed, clinically stable, extremely premature infants ( ∼ 26-wk gestation) at two glucose infusion rates (6.2±0.4 and 9.5±0.5 mg/kg per min). We also assessed whether an increase in glucose delivery suppresses proteolysis by measuring the Ra of phenylalanine and leucine. Glucose Ra (and utilization) increased significantly at the higher glucose infusion rate (7.9±0.5 vs. 9.8±0.6 mg/kg per min). Glucose production persisted at the lower glucose infusion rate but was suppressed to nearly zero at the higher rate (1.7±0.5 vs. 0.3±0.1 mg/kg per min). Proteolysis was unaffected by the higher glucose infusion rate as reflected by no change in the rates of appearance of either phenylalanine (96±5 vs. 95±3 μmol/kg per h) or leucine (285±20 vs. 283±14 μmol/kg per h). Thus, clinically stable, extremely premature infants suppress glucose production and increase glucose utilization in response to increased glucose infusion, demonstrating no inherent immaturity of these processes. In contrast, increasing the rate of glucose delivery results in no change in whole body proteolysis in these infants. The regulation of proteolysis in this population remains to be defined.

Original languageEnglish
Pages (from-to)1752-1758
Number of pages7
JournalJournal of Clinical Investigation
Volume92
Issue number4
StatePublished - 1993

Fingerprint

Proteolysis
Newborn Infant
Glucose
Extremely Premature Infants
Phenylalanine
Leucine

Keywords

  • Glucose utilization
  • Leucine
  • Phenylalanine
  • Protein turnover
  • Stable isotope tracers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Intravenous glucose suppresses glucose production but not proteolysis in extremely premature newborns. / Hertz, David E.; Karn, Cheryl A.; Liu, Ya Mei; Liechty, Edward A.; Denne, Scott.

In: Journal of Clinical Investigation, Vol. 92, No. 4, 1993, p. 1752-1758.

Research output: Contribution to journalArticle

Hertz, David E. ; Karn, Cheryl A. ; Liu, Ya Mei ; Liechty, Edward A. ; Denne, Scott. / Intravenous glucose suppresses glucose production but not proteolysis in extremely premature newborns. In: Journal of Clinical Investigation. 1993 ; Vol. 92, No. 4. pp. 1752-1758.
@article{76e018b007804c979a17f2172c9397b6,
title = "Intravenous glucose suppresses glucose production but not proteolysis in extremely premature newborns",
abstract = "To ascertain whether the inability to suppress glucose production and increase glucose utilization in response to glucose infusion is an inherent characteristic of immature individuals, we determined glucose rate of appearance (Ra) in minimally stressed, clinically stable, extremely premature infants ( ∼ 26-wk gestation) at two glucose infusion rates (6.2±0.4 and 9.5±0.5 mg/kg per min). We also assessed whether an increase in glucose delivery suppresses proteolysis by measuring the Ra of phenylalanine and leucine. Glucose Ra (and utilization) increased significantly at the higher glucose infusion rate (7.9±0.5 vs. 9.8±0.6 mg/kg per min). Glucose production persisted at the lower glucose infusion rate but was suppressed to nearly zero at the higher rate (1.7±0.5 vs. 0.3±0.1 mg/kg per min). Proteolysis was unaffected by the higher glucose infusion rate as reflected by no change in the rates of appearance of either phenylalanine (96±5 vs. 95±3 μmol/kg per h) or leucine (285±20 vs. 283±14 μmol/kg per h). Thus, clinically stable, extremely premature infants suppress glucose production and increase glucose utilization in response to increased glucose infusion, demonstrating no inherent immaturity of these processes. In contrast, increasing the rate of glucose delivery results in no change in whole body proteolysis in these infants. The regulation of proteolysis in this population remains to be defined.",
keywords = "Glucose utilization, Leucine, Phenylalanine, Protein turnover, Stable isotope tracers",
author = "Hertz, {David E.} and Karn, {Cheryl A.} and Liu, {Ya Mei} and Liechty, {Edward A.} and Scott Denne",
year = "1993",
language = "English",
volume = "92",
pages = "1752--1758",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

TY - JOUR

T1 - Intravenous glucose suppresses glucose production but not proteolysis in extremely premature newborns

AU - Hertz, David E.

AU - Karn, Cheryl A.

AU - Liu, Ya Mei

AU - Liechty, Edward A.

AU - Denne, Scott

PY - 1993

Y1 - 1993

N2 - To ascertain whether the inability to suppress glucose production and increase glucose utilization in response to glucose infusion is an inherent characteristic of immature individuals, we determined glucose rate of appearance (Ra) in minimally stressed, clinically stable, extremely premature infants ( ∼ 26-wk gestation) at two glucose infusion rates (6.2±0.4 and 9.5±0.5 mg/kg per min). We also assessed whether an increase in glucose delivery suppresses proteolysis by measuring the Ra of phenylalanine and leucine. Glucose Ra (and utilization) increased significantly at the higher glucose infusion rate (7.9±0.5 vs. 9.8±0.6 mg/kg per min). Glucose production persisted at the lower glucose infusion rate but was suppressed to nearly zero at the higher rate (1.7±0.5 vs. 0.3±0.1 mg/kg per min). Proteolysis was unaffected by the higher glucose infusion rate as reflected by no change in the rates of appearance of either phenylalanine (96±5 vs. 95±3 μmol/kg per h) or leucine (285±20 vs. 283±14 μmol/kg per h). Thus, clinically stable, extremely premature infants suppress glucose production and increase glucose utilization in response to increased glucose infusion, demonstrating no inherent immaturity of these processes. In contrast, increasing the rate of glucose delivery results in no change in whole body proteolysis in these infants. The regulation of proteolysis in this population remains to be defined.

AB - To ascertain whether the inability to suppress glucose production and increase glucose utilization in response to glucose infusion is an inherent characteristic of immature individuals, we determined glucose rate of appearance (Ra) in minimally stressed, clinically stable, extremely premature infants ( ∼ 26-wk gestation) at two glucose infusion rates (6.2±0.4 and 9.5±0.5 mg/kg per min). We also assessed whether an increase in glucose delivery suppresses proteolysis by measuring the Ra of phenylalanine and leucine. Glucose Ra (and utilization) increased significantly at the higher glucose infusion rate (7.9±0.5 vs. 9.8±0.6 mg/kg per min). Glucose production persisted at the lower glucose infusion rate but was suppressed to nearly zero at the higher rate (1.7±0.5 vs. 0.3±0.1 mg/kg per min). Proteolysis was unaffected by the higher glucose infusion rate as reflected by no change in the rates of appearance of either phenylalanine (96±5 vs. 95±3 μmol/kg per h) or leucine (285±20 vs. 283±14 μmol/kg per h). Thus, clinically stable, extremely premature infants suppress glucose production and increase glucose utilization in response to increased glucose infusion, demonstrating no inherent immaturity of these processes. In contrast, increasing the rate of glucose delivery results in no change in whole body proteolysis in these infants. The regulation of proteolysis in this population remains to be defined.

KW - Glucose utilization

KW - Leucine

KW - Phenylalanine

KW - Protein turnover

KW - Stable isotope tracers

UR - http://www.scopus.com/inward/record.url?scp=0027448791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027448791&partnerID=8YFLogxK

M3 - Article

VL - 92

SP - 1752

EP - 1758

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -